Investigational Drug Information for LOXO-305
✉ Email this page to a colleague
What is the development status for investigational drug LOXO-305?
LOXO-305 is an investigational drug.
There have been 26 clinical trials for LOXO-305.
The most recent clinical trial was a Phase 1 trial, which was initiated on March 9th 2021.
The most common disease conditions in clinical trials are Lymphoma, Leukemia, Lymphoid, and Leukemia, Lymphocytic, Chronic, B-Cell. The leading clinical trial sponsors are Loxo Oncology, Inc., Eli Lilly and Company, and M.D. Anderson Cancer Center.
There are four US patents protecting this investigational drug and sixty-two international patents.
Summary for LOXO-305
| US Patents | 4 |
| International Patents | 62 |
| US Patent Applications | 9 |
| WIPO Patent Applications | 6 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 1 (2021-03-09) |
| Vendors | 29 |
Recent Clinical Trials for LOXO-305
| Title | Sponsor | Phase |
|---|---|---|
| LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies | Medical College of Wisconsin | Phase 1 |
| A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis | Eli Lilly and Company | Phase 2 |
| A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis | Loxo Oncology, Inc. | Phase 2 |
Clinical Trial Summary for LOXO-305
Top disease conditions for LOXO-305
Top clinical trial sponsors for LOXO-305
US Patents for LOXO-305
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| LOXO-305 | ⤷ Sign Up | Compounds useful as kinase inhibitors | Loxo Oncology, Inc. (Stamford, CT) | ⤷ Sign Up |
| LOXO-305 | ⤷ Sign Up | Compounds useful as kinase inhibitors | Loxo Oncology Inc. | ⤷ Sign Up |
| LOXO-305 | ⤷ Sign Up | Compounds useful as kinase inhibitors | Loxo Oncology, Inc. (Stamford, CT) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for LOXO-305
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| LOXO-305 | Australia | AU2016373530 | 2035-12-16 | ⤷ Sign Up |
| LOXO-305 | Australia | AU2021201811 | 2035-12-16 | ⤷ Sign Up |
| LOXO-305 | Australia | AU2021225161 | 2035-12-16 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
